Erythrocyte-associated apolipoprotein B and its relationship with clinical and subclinical atherosclerosis

European Journal of Clinical Investigation

Volumn 42, Issue 4, 2012, Pages 365-370

  Bovenberg, Sarah A ^a   Klop, Boudewijn ^a   Alipour, Arash ^a   Martinez Hervas, Sergio ^b   Westzaan, Andrew ^a   van de Geijn, Gert Jan M ^a   Janssen, Hans W J ^a   Njo, Tjin ^a   Birnie, Erwin ^a   van Mechelen, Rob ^a   Rietveld, Arie P ^a   Elte, Jan Willem F ^a   Castro Cabezas, Manuel ^a  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Atherosclerosis; Endothelium; Erythrocytes; Intima media thickness; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ANGIOGRAPHY; CROSS-SECTIONAL STUDIES; ERYTHROCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84858280671     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02591.x     Document Type: Article

References (26)

1. Stalenhoef FH, Malloy MJ, Kane JP, Havel RJ. Metabolism of apoB-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans. Proc Natl Acad Sci USA 1984;81:1839-43.
2. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990;82:1574-94.
3. Elovson J, Chatterton JE, Bell GT, Shumaker VN, Reuben MA, Puppione DL et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988;29:1461-73.
4. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
5. Walldius G, Junger I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259:493-519.
6. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 2003;361:777-80.
7. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a 5year follow-up of men in the Québec Cardiovascular Study. Circulation 1996;94:273-8.
8. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P et al. Apo B versus cholesterol in estimating cardiovascular risk and guiding therapy: report of the thirty-person/ten country panel. J Intern Med 2006;259:247-58.
9. Verseyden C, Meijssen S, Castro Cabezas M. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in Large, triglyceride-rich lipoproteins in familial combined hyperlipidaemia. J Clin Endocrinol Metab 2004;89:5021-9.
10. Alipour A, van Oostrom AJ, Izraeljan A, Verseyden C, Collins JM, Frayn KN et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:792-7.
11. Gower RM, Wu H, Foster GA, Deveraj S, Jialal I, Ballantyne CM et al. CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2011;31:160-6.
12. Hui DY, Noel JG, Harmony JA. Binding of plasma low density lipoproteins to erythrocytes. Biochim Biophys Acta 1981;664:513-26.
13. Hui DY, Harmony JA. Interaction of plasma lipoproteins with erythrocytes. I. Alteration of erythrocyte morphology. Biochim Biophys Acta 1979;550:407-24.
14. WHO. ICD-10 2nd Edition, International Statistical Classification of Disease and Health Related Problems. Geneva: World Health Organization, 2005.
15. Elm von E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8.
16. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
17. Matthan NR, Jalbert SM, Barrett HR, Dolnikowsky GG, Schaefer EJ, Lichtenstein AH. Gender-specific differences in the kinetics of nonfasting TRL, IDL, and LDL apolipoprotein B-100 in men and premenopausal women. Arterioscler Thromb Vasc Biol 2008;28:1838-43.
18. Gardner CD, Tribble DL, Young DR, Ahn D, Fortmann SP. Population frequency distributions of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B in healthy men and women and associations with age, gender, hormonal status, and sex hormone use: the Stanford Five City Project. Prev Med 2000;31:335-345.
19. Bovenberg SA, Alipour A, Elte JWF, Rietveld AP, Janssen JW, Geijn van de GJ et al. Cell-mediated lipoprotein transport: a novel anti-atherogenic concept. Atheroscler Suppl 2010;11:25-9.
20. Pascual M, Schifferli JA. Another function of erythrocytes: transport of circulating immune complexes. Infusionsther Transfusionsmed 1995;22:310-5.
21. Cornacoff JB, Hebert LA, Smead WL, VanAman ME, Birmingham DJ, Waxman FJ. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983;71:236-47.
22. Nardin A, Lindorfer MA, Taylor RP. How are immune complexes bound to the primate erythrocyte complement receptor transferred to acceptor phagocytic cells? Mol Immunol 1999;36:827-35.
23. Eagle K, Ginsburg G, Musunuru K, Aird W, Balaban R, Bennet S et al. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national Heart, Lung and Blood Institute working group. Circulation 2010;121:1447-54.
24. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009;29:424-30.
25. Schmidt C, Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 2009;205:284-9.
26. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16.